Brokerages Expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Will Post Quarterly Sales of $2.90 Million

Equities research analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Rating) to post sales of $2.90 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Rhythm Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.30 million and the highest estimate coming in at $3.50 million. Rhythm Pharmaceuticals […]

Related Keywords

Stifel Nicolaus ,Rhythm Pharmaceuticals Company Profile Get Rating ,Morgan Stanley ,Primecap Management Co ,Goldman Sachs Group Inc ,Zacks Investment Research ,Blackrock Inc ,Rhythm Pharmaceuticals ,Nasdaq ,Rhythm Pharmaceuticals Inc ,Canaccord Genuity Group ,Hermes Inc ,Get Rating ,Rhythm Pharmaceutical ,Investment Research ,Genuity Group ,Sachs Group ,Rock Springs Capital Management ,Springs Capital Management ,Pharmaceuticals Company Profile ,Nasdaq Rytm ,Rytm ,Medical ,Ratings ,Consensus ,